Takeda Pharmaceutical Co. $TAK Shares Sold by Heritage Investors Management Corp

Key Points

• Heritage Investors Management cut its Takeda Pharmaceutical holdings by 63.2% in the third quarter, selling 51,750 shares and retaining 30,189 shares worth approximately $549,000.
• Institutional ownership changes were mixed: several investors increased their positions or initiated stakes, while hedge funds and other institutions collectively owned 9.17% of Takeda’s stock.
• Takeda shares opened at $20.89, near the company’s 52-week high of $21.22. Analysts’ consensus rating is “Moderate Buy,” with two Buy ratings and two Hold ratings.

Heritage Investors Management Corp cut its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 63.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,189 shares of the company's stock after selling 51,750 shares during the period. Heritage Investors Management Corp's holdings in Takeda Pharmaceutical were worth $549,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in TAK. Nisa Investment Advisors LLC grew its stake in Takeda Pharmaceutical by 28.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,306 shares of the company's stock worth $42,000 after buying an additional 515 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Takeda Pharmaceutical in the third quarter worth about $59,000. Rockefeller Capital Management L.P. boosted its holdings in Takeda Pharmaceutical by 30.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company's stock worth $81,000 after acquiring an additional 1,215 shares in the last quarter. Pinnacle Wealth Planning Services Inc. boosted its holdings in Takeda Pharmaceutical by 9.9% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 7,881 shares of the company's stock worth $143,000 after acquiring an additional 711 shares in the last quarter. Finally, Walkner Condon Financial Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the first quarter worth about $186,000. Hedge funds and other institutional investors own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Zacks Research downgraded shares of Takeda Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 1st. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Finally, Weiss Ratings raised shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy".

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $20.89 on Tuesday. Takeda Pharmaceutical Co. has a fifty-two week low of $13.35 and a fifty-two week high of $21.22. The firm has a market capitalization of $66.95 billion, a P/E ratio of 11.99 and a beta of -0.07. The stock has a 50-day simple moving average of $18.90 and a two-hundred day simple moving average of $17.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14.

Insider Activity

In related news, insider Giles Platford sold 31,083 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $531,519.30. Following the completion of the sale, the insider directly owned 315,838 shares in the company, valued at approximately $5,400,829.80. The trade was a 8.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Andrew Plump sold 165,393 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30. Following the completion of the sale, the insider owned 766,569 shares of the company's stock, valued at $13,108,329.90. This trade represents a 17.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 627,457 shares of company stock worth $10,981,175. Company insiders own 0.04% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda's portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.